FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula I:
,
where: R1 is CH3 or CD3; R2 and R3 each independently represent H or D; R4 and R5 each independently represent H or D; provided that R2, R3, R4 and R5 are not all H when R1 is CH3, and where D is deuterium; in free form or salt form.
EFFECT: obtaining novel compounds which can be used for treating diseases involving 5-HT2A receptor, a serotonin transporter (SERT), and/or pathways, including D1/D2 signal systems of dopamine receptors, and/or treating residual symptoms.
10 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
ORGANIC COMPOUNDS | 2017 |
|
RU2743513C2 |
PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT OR PREVENTION OF DISORDER OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2776800C2 |
ORGANIC COMPOUNDS | 2011 |
|
RU2591194C2 |
ORGANIC COMPOUNDS | 2018 |
|
RU2777366C2 |
ORGANIC COMPOUNDS | 2018 |
|
RU2780002C2 |
NEW METHODS | 2014 |
|
RU2682658C1 |
THE SELECTIVE INVERSE AGONISTS OF SEROTONIN RECEPTORS AS MEDICATION TO CURE DISEASES | 2005 |
|
RU2442607C2 |
LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
Authors
Dates
2020-07-31—Published
2015-04-03—Filed